Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total

P 1 (3)

P 2 (1)

Trial Status

Not Yet Recruiting1

Withdrawn1

Active Not Recruiting1

Completed1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT05286801Phase 1Active Not Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

NCT07447076Phase 2Not Yet RecruitingPrimary

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

NCT04521946Phase 1Withdrawn

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

NCT03387020Phase 1Completed

Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Showing all 4 trials

Recurrent Atypical Teratoid/Rhabdoid Tumor